Haisco(SZ:002653) Xin Lang Cai Jing·2026-02-04 01:34Core Viewpoint - On February 3, 2025, Haikang's stock fell by 5.47% with a trading volume of 430 million yuan, indicating market volatility and investor sentiment concerns [1] Financing Summary - On February 3, Haikang had a financing buy-in amount of 14.89 million yuan and a financing repayment of 13.57 million yuan, resulting in a net financing buy of 1.32 million yuan [1] - As of February 3, the total financing and securities lending balance for Haikang was 75.17 million yuan, with a financing balance of 68.38 million yuan, accounting for 0.13% of the circulating market value, which is above the 80th percentile of the past year [1] - The securities lending aspect showed that 900 shares were repaid and 1,300 shares were sold on February 3, with a selling amount of 61,700 yuan, while the securities lending balance was 6.79 million yuan, below the 20th percentile of the past year [1] Business Performance - As of September 30, 2025, Haikang reported a total revenue of 3.3 billion yuan for the first nine months, representing a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2] - The company has cumulatively distributed dividends of 3.673 billion yuan since its A-share listing, with 687 million yuan distributed over the past three years [2] Shareholder Structure - As of September 30, 2025, Haikang had 12,900 shareholders, an increase of 12.87% from the previous period, with an average of 37,342 circulating shares per shareholder, a decrease of 11.40% [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]